New research into Alzheimer’s drug

Date:

Lecanemab inhibits the disease, but has side effects

The New England Journal of Medicine has published new results on the drug candidate lecanemab for early-stage Alzheimer’s disease. It prevents the disease, but also has side effects.

Lecanemab is a monoclonal antibody that binds to amyloid proteins that are elevated in the brain in Alzheimer’s disease. Lecanemab was actually able to affect these amyloid proteins. But if the disease persists in the meantime, it won’t do much good.

The good news in this new study is the positive effect it measures on the symptoms of the disease. Participants who took this drug became 27 percent less worse than participants who took a placebo (dummy drug). This is a modest effect, unfortunately for lecacemab users, that comes with more side effects such as swelling and bleeding in the brain.

More research is needed

The study involved nearly 1,800 people ages 50 to 90 with early-stage Alzheimer’s disease. They had a scan or measurement that showed they had mild cognitive problems (such as memory loss) and high levels of these amyloid proteins.

The study lasted 18 months. Researchers are still too short on the efficacy and safety of lecanemab in the early stages of Alzheimer’s disease to get a good picture. They propose a longer follow-up study.

  • Author: Helen Crown
  • Source: Gezondheids Net

    Source link

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    Share post:

    Subscribe

    Popular

    More like this
    Related

    Expert advice against the dollar ‘roller coaster’

    Companies that are usually importers should be prepared for...

    The Tiburonas make their debut with a 0-0 draw against Deportes Tolima

    Junior did not start 0-0 against Deportes Tolima on...

    Indonesia may be closer

    After beating Paraguay 3-0, Colombia regained confidence in the...